- Home
- MVIS vs PROK Comparison
MVIS vs PROK Comparison
Compare MVIS & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVIS
- PROK
- Stock Information
- Founded
- MVIS 1993
- PROK 2015
- Country
- MVIS United States
- PROK United States
- Employees
- MVIS N/A
- PROK N/A
- Industry
- MVIS Industrial Machinery/Components
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MVIS Technology
- PROK Health Care
- Exchange
- MVIS Nasdaq
- PROK Nasdaq
- Market Cap
- MVIS 234.3M
- PROK 237.4M
- IPO Year
- MVIS 1996
- PROK N/A
- Fundamental
- Price
- MVIS $1.03
- PROK $1.77
- Analyst Decision
- MVIS Hold
- PROK Buy
- Analyst Count
- MVIS 2
- PROK 5
- Target Price
- MVIS $3.00
- PROK $4.50
- AVG Volume (30 Days)
- MVIS 3.0M
- PROK 409.9K
- Earning Date
- MVIS 11-07-2024
- PROK 11-12-2024
- Dividend Yield
- MVIS N/A
- PROK N/A
- EPS Growth
- MVIS N/A
- PROK N/A
- EPS
- MVIS N/A
- PROK N/A
- Revenue
- MVIS $8,147,000.00
- PROK N/A
- Revenue This Year
- MVIS $24.78
- PROK N/A
- Revenue Next Year
- MVIS $451.78
- PROK N/A
- P/E Ratio
- MVIS N/A
- PROK N/A
- Revenue Growth
- MVIS 277.53
- PROK N/A
- 52 Week Low
- MVIS $0.80
- PROK $1.18
- 52 Week High
- MVIS $2.98
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- MVIS 51.19
- PROK 46.57
- Support Level
- MVIS $0.82
- PROK $1.75
- Resistance Level
- MVIS $0.85
- PROK $2.03
- Average True Range (ATR)
- MVIS 0.06
- PROK 0.19
- MACD
- MVIS 0.01
- PROK -0.02
- Stochastic Oscillator
- MVIS 66.67
- PROK 23.76
About MVIS MicroVision Inc.
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.